Bio­gen, Ei­sai are push­ing for an­oth­er ac­cel­er­at­ed Alzheimer's OK — this time for BAN2401

Now that the door at the FDA has been opened wide for Alzheimer’s drugs that can demon­strate a re­duc­tion in amy­loid, Bio­gen and its part­ners at Ei­sai are push­ing for a quick OK on the next drug to fol­low in the con­tro­ver­sial path of ad­u­canum­ab.

In a pre­sen­ta­tion to an­a­lysts, Ei­sai neu­rol­o­gy chief Ivan Che­ung out­lined some bull­ish ex­pec­ta­tions for their new­ly-ap­proved treat­ment and set the stage for what he be­lieves will be a fast fol­low for BAN2401 (lecanemab) — af­ter a dry spell in new drug de­vel­op­ment that’s last­ed close to 20 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER